CX3CL1



CX3CL1

Q1QQ1H2HH2L3LL3G4GG4M5MM5T6TT6K7KK7C8CC8E9EE9I10II10M11MM11C12CC12D13DD13K14KK14M15MM15T16TT16S17SS17R18RR18I19II19P20PP20V21VV21A22AA22L23LL23L24LL24I25II25R26RR26Y27YY27Q28QQ28L29LL29N30NN30Q31QQ31E32EE32S33SS33C34CC34G35GG35K36KK36R37RR37A38AA38I39II39V40VV40L41LL41E42EE42T43TT43T44TT44Q45QQ45H46HH46R47RR47... and 324 more residue(s)...... and 324 more residue(s)

SMILES None
InChIKey None
Sequence QHLGMTKCEIMCDKMTSRIPVALLIRYQLNQESCGKRAIVLETTQHRRFCADPKEKWVQDAMKHLDHQAAALTKNGGKFEKRVDNVTPGITLATRGLSPSALTKPESATLEDLALELTTISQEARGTMGTSQEPPAAVTGSSLSTSEAQDAGLTAKPQSIGSFEAADISTTVWPSPAVYQSGSSSWAEEKATESPSTTAPSPQVSTTSPSTPEENVGSEGQPPWVQGQDLSPEKSLGSEEINPVHTDNFQERGPGNTVHPSVAPISSEETPSPELVASGSQAPKIEEPIHATADPQKLSVLITPVPDTQAATRRQAVGLLAFLGLLFCLGVAMFAYQSLQGCPRKMAGEMVEGLRYVPRSCGSNSYVLVPV

Chemical Properties

Hydrogen bond acceptors None
Hydrogen bond donors None
Rotatable bonds None
Molecular weight (Da)

Database connections


No bioactivity data available.

CX3CL1

Q1QQ1H2HH2L3LL3G4GG4M5MM5T6TT6K7KK7C8CC8E9EE9I10II10M11MM11C12CC12D13DD13K14KK14M15MM15T16TT16S17SS17R18RR18I19II19P20PP20V21VV21A22AA22L23LL23L24LL24I25II25R26RR26Y27YY27Q28QQ28L29LL29N30NN30Q31QQ31E32EE32S33SS33C34CC34G35GG35K36KK36R37RR37A38AA38I39II39V40VV40L41LL41E42EE42T43TT43T44TT44Q45QQ45H46HH46R47RR47... and 324 more residue(s)...... and 324 more residue(s)

Drug properties

Molecular type Peptide
Physiological/Surrogate Endogenous
Approved drug No

Distribution across phases (no. indications)

Phase I 0
Phase II 0
Phase III 0
Phase IV 0

Database connections


Compound is not listed as a drug.